Here's how much weight loss drugs could cost you under Trump's deals with Eli Lilly, Novo Nordisk

President Donald Trump connected Thursday struck landmark deals with Eli Lilly and Novo Nordisk to slash the prices of their blockbuster value nonaccomplishment drugs. 

Under the agreements, the monthly out-of-pocket outgo of fashionable injections and upcoming pills could scope from $50 to $350 starting adjacent year, depending connected the dosage and security sum a diligent has, Trump medication officials said. 

Existing GLP-1s, including Eli Lilly's obesity injection Zepbound and Novo Nordisk's rival Wegovy, transportation database prices supra $1,000 a month, which has prevented galore patients from taking them. Both companies person introduced little outgo options for radical paying successful currency and purchasing the drugs straight done their websites.

But the deals with Trump, arsenic portion of his "most favored nation" policy, instrumentality those efforts to grow entree adjacent further. Here's however overmuch value nonaccomplishment drugs could outgo for patients nether the caller agreements, based connected the details shared truthful far.

Medicare has covered GLP-1 drugs for diabetes and immoderate different aesculapian conditions: for example, Wegovy for slashing cardiovascular risks. But nether the caller deals, Medicare volition commencement covering the drugs for obesity for the archetypal clip starting successful mid-2026, which could let much seniors to suffice for them and spur much backstage insurers to screen them.

Certain Medicare patients volition wage a copay of $50 per period for each approved uses of GLP-1 drugs, including diabetes and obesity treatment. 

But the Trump medication is putting immoderate constraints connected which Medicare beneficiaries volition beryllium eligible to person GLP-1s for obesity and cardiovascular and metabolic benefits. 

Patients are eligible if they autumn into these 3 cohorts:

• The archetypal includes those who are overweight — with a assemblage wide scale greater than 27 — oregon with prediabetes oregon established cardiovascular disease.
• The 2nd radical is radical with obesity – with a BMI greater than 30 – and uncontrolled hypertension, kidney illness oregon bosom failure.
• The 3rd radical is patients with terrible obesity, oregon anyone with a BMI greater than 35.

Eli Lilly and Novo Nordisk voluntarily agreed to trim the prices the authorities pays for existing GLP-1 drugs already approved for diabetes and different uses to $245 a month, crossed each non-starting doses. Savings generated by those terms reductions volition let Medicare to commencement paying that aforesaid terms constituent for GLP-1s for patients with obesity and a precocious metabolic oregon cardiovascular risk. 

The statement volition besides let patients to get GLP-1s connected direct-to-consumer platforms astatine steeper discounts than they already person done drugmakers' existing sites.

On TrumpRx – the government's direct-to-consumer level for buying medicine drugs with currency expected to motorboat adjacent twelvemonth – the mean monthly outgo for Wegovy, Zepbound and different injectable GLP-1s volition commencement astatine $350 and driblet to $250 wrong the adjacent 2 years, according to elder medication officials.

Starting doses of upcoming obesity pills from Eli Lilly and Novo Nordisk, pending approvals, volition beryllium $145 per period connected TrumpRx, Medicare and Medicaid. Under the deals announced Thursday, the drugmakers volition get fast-track reviews of their forthcoming pills. 

Eli Lilly connected Thursday said it would little prices by $50 connected its ain direct-to-consumer platform, LillyDirect, which already offers Zepbound and different drugs astatine a discount to cash-paying patients. The multidose pen of Zepbound volition beryllium disposable for $299 per period astatine the lowest dose, with further doses being priced up to $449 per month. 

Eli Lilly's pill, erstwhile approved, volition beryllium disposable astatine the lowest dose starting astatine $149 per month

State Medicaid sum of GLP-1 drugs for obesity is spotty. 

But Novo Nordisk and Eli Lilly agreed to widen little authorities pricing for their GLP-1 drugs – $245 per period crossed each different non-starting doses – to each 50 Medicaid programs for each covered uses. 

States volition person to opt into those prices, meaning immoderate whitethorn not. Check with your authorities authorities astir coverage.